In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Esperion (ESPR), with a price target of $83.00. The company’s shares closed last Monday at $61.76.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 7.1% and a 44.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Pacira Pharmaceuticals, and Rhythm Pharmaceuticals.
Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $90.57, representing a 31.9% upside. In a report issued on February 18, Credit Suisse also maintained a Buy rating on the stock with a $90.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $76.98 and a one-year low of $33.13. Currently, Esperion has an average volume of 593.7K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESPR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
